{{Rsnum
|rsid=12050217
|Gene=BDKRB1
|Chromosome=14
|position=96262416
|Orientation=plus
|GMAF=0.2713
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=BDKRB1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 66.4 | 29.2 | 4.4
| HCB | 38.0 | 43.1 | 19.0
| JPT | 38.1 | 51.3 | 10.6
| YRI | 64.6 | 32.0 | 3.4
| ASW | 64.9 | 29.8 | 5.3
| CHB | 38.0 | 43.1 | 19.0
| CHD | 33.9 | 47.7 | 18.3
| GIH | 61.4 | 34.7 | 4.0
| LWK | 70.9 | 25.5 | 3.6
| MEX | 37.9 | 44.8 | 17.2
| MKK | 64.1 | 32.1 | 3.8
| TSI | 62.7 | 32.4 | 4.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12050217
|Name_s=
|Gene_s=BDKRB1
|Feature=
|Evidence=PubMed ID:20712529
|Annotation=Risk or phenotype-associated allele: A. AA homozygotes had reduced HR for cardiac events while treated with perindopril. Study size: 8907. Study population/ethnicity: PERGENE study; EUROPA trial; European; White. Significance metric(s): HR = 0.64 (0.55-0.78), p = 0.012. Type of association: CO
|Drugs=perindopril
|Drug Classes=ACE INHIBITORS, PLAIN
|Diseases=Coronary Artery Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA165378310
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}